Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women. However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined. The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma. The animals were maternally exposed to 2.5 or 5.0 mg/kg of busulfan on gestation day 14 to reduce primordial follicles, and were then initiated by intrauterine treatment with N-ethyl-N'-nitro-N-nitrosoguanidine at 11 weeks of age. Both busulfan treatment doses caused earlier occurrence of persistent estrus, with dose-dependence as compared to controls. At 15 months of age, the rats were euthanized. The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment. Morphologically, the ovaries exposed to busulfan treatment exhibited severe atrophy, with few or no follicles and corpus lutea. Serum 17beta-estradiol (E2), progesterone, and inhibin levels were significantly decreased in the busulfan treatment groups, with a clear dose-relation. Interestingly, only the 5.0 mg/kg busulfan treatment elevated the E2/progesterone ratio. These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
Yoshida
Midori
M
Department of Pathology, Sasaki Institute, Tokyo, Japan. midoriy@sasaki.or.jp
Watanabe
Gen
G
Shirota
Mariko
M
Maekawa
Akihiko
A
Taya
Kazuyoshi
K
D000230:Adenocarcinoma / Q000209:etiology*; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001284:Atrophy; D002066:Busulfan / Q000494:pharmacology*; D016889:Endometrial Neoplasms / Q000209:etiology*; D030762:Estrous Cycle / Q000187:drug effects; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D009867:Oogonia / Q000187:drug effects; D009929:Organ Size; D010049:Ovarian Diseases / Q000139:chemically induced* / Q000150:complications; D006080:Ovarian Follicle / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D011922:Rats, Mutant Strains
D018906:Antineoplastic Agents, Alkylating; D012739:Gonadal Steroid Hormones; D002066:Busulfan